WO2007119859A1 - タンパク質複合体およびその製造方法 - Google Patents
タンパク質複合体およびその製造方法 Download PDFInfo
- Publication number
- WO2007119859A1 WO2007119859A1 PCT/JP2007/058381 JP2007058381W WO2007119859A1 WO 2007119859 A1 WO2007119859 A1 WO 2007119859A1 JP 2007058381 W JP2007058381 W JP 2007058381W WO 2007119859 A1 WO2007119859 A1 WO 2007119859A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- mag
- antigen
- producing
- cta
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 title claims description 78
- 102000004169 proteins and genes Human genes 0.000 title claims description 74
- 238000000034 method Methods 0.000 title abstract description 28
- 108091007433 antigens Proteins 0.000 claims abstract description 128
- 102000036639 antigens Human genes 0.000 claims abstract description 128
- 239000000427 antigen Substances 0.000 claims abstract description 83
- 150000004676 glycans Chemical class 0.000 claims abstract description 39
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 39
- 239000005017 polysaccharide Substances 0.000 claims abstract description 39
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 20
- 235000018102 proteins Nutrition 0.000 claims description 73
- 206010028980 Neoplasm Diseases 0.000 claims description 58
- 201000011510 cancer Diseases 0.000 claims description 56
- 229960005486 vaccine Drugs 0.000 claims description 40
- 210000001550 testis Anatomy 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 108091065810 E family Proteins 0.000 claims description 19
- 238000000746 purification Methods 0.000 claims description 13
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 238000006277 sulfonation reaction Methods 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 230000000536 complexating effect Effects 0.000 claims description 5
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 claims description 5
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 14
- 238000005538 encapsulation Methods 0.000 abstract description 2
- 238000004925 denaturation Methods 0.000 abstract 1
- 230000036425 denaturation Effects 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 26
- 239000004202 carbamide Substances 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 238000010968 computed tomography angiography Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229940023143 protein vaccine Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000001012 protector Effects 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- 229920001218 Pullulan Polymers 0.000 description 4
- 239000004373 Pullulan Substances 0.000 description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 229960004198 guanidine Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019423 pullulan Nutrition 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 125000002328 sterol group Chemical group 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 229920000057 Mannan Polymers 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- -1 6-sitosterol Chemical compound 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- HPQYKCJIWQFJMS-UHFFFAOYSA-N tetrathionic acid Chemical compound OS(=O)(=O)SSS(O)(=O)=O HPQYKCJIWQFJMS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150000419 GPC gene Proteins 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 235000019892 Stellar Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- OMCWXFSQPKBREP-UHFFFAOYSA-N acetic acid;hydroiodide Chemical compound I.CC(O)=O OMCWXFSQPKBREP-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N ergosterol group Chemical group [C@@H]1(CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)\C=C\[C@H](C)C(C)C DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- BVJUXXYBIMHHDW-UHFFFAOYSA-N iodane Chemical compound I.I BVJUXXYBIMHHDW-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Definitions
- the present invention relates to a protein complex and a method for producing the same, and more particularly to a protein antigen for an anti-cancer protein vaccine and a method for producing the same.
- the present invention is particularly preferably applicable to a cancer-specific protein antigen of an anti-cancer protein vaccine having two or more cysteine residues in the molecule and a method for producing the same.
- the present invention oxidizes a cysteine residue of a cancer-specific protein antigen of an anti-cancer protein vaccine having two or more cystine residues in the molecule, for example, cancer testis antigen (CTA).
- CTA cancer testis antigen
- the present invention relates to a production method which is protected by selective sulfonation and efficiently purified. Background art
- the present invention can be applied without particular limitation to a protein having two or more cysteine residues in the molecule.
- CTA cancer testis antigen
- Non-patent Document 1 van der Brugg en P, et al., Science; 2 5 4: 1 6 4 3-7 (1 9 9 1)
- Non-patent Document 2 De Plaen E, et al., Immunogene tics; 40: 3 60-9 (1 9 94)
- Non-Patent Document 3 Rogner UC, et al., Genomics. 2 9: 7 2 5-3 1 (1 9 9 5)
- CTA Cancer testis antigen
- Protein-based vaccines can be used to efficiently deliver cancer-specific antigens to antigen-presenting cells (eg, dendritic cells), or cancer-specific antigens.
- a cancer-specific antigen is sometimes embedded in a polymer carrier such as a ribosome.
- a polymer carrier such as a ribosome.
- a hydrophobic polysaccharide for example, CHP
- CHP has the property of facilitating antigen-presenting cells to present the antigen by embedding the entire cancer-specific antigen, and is stable as a formulation by protecting the cancer-specific antigen within the CHP. It also has the effect of improving the performance.
- Patent Document 1 As such a polymer carrier, ISC OMATR IX adjuvant is also known.
- Patent Document X Patent Document X; WO 2 0 0 5 0 3 2 4 7 5)
- the polymer carrier used as the embedding agent include well-known materials such as liposomes and iscomatrix.
- Ribosomes are commonly used for these purposes and are well known to those skilled in the art, and can be used in combination with phospholipids and other cholesterol and various substances, and with antibodies and magnetic particles. It is used in the DDS system with the function of concentrating on the target site.
- a vaccine containing buenolol extract of leukemia cells Shibata R. et al., (1 9 9 1) Int J Cancer. May 3 0; 4 8 (3): 4 3 4-4 2
- vaccines from membrane proteins (Sunamoto J. et al., (190 years) Ann NY Acad Sci. 6 1 3: 1 1 6-2 7).
- Iscoma Rix is a known substance that can be used as a vaccine by embedding cancer antigens, and is composed of saponin, cholesterol and phospholipids. Development is underway at CSL in Australia, and clinical trials have already been reported. (For example, B u t t s
- cancer-specific antigens such as CTA can be expressed and produced by recombinant E. coli, it is usually necessary to go through several purification steps in order to ensure pharmaceutical grade quality.
- H is — Tag, a tag that forms a chelate with a metal ion in a sequence of multiple histidines, added to the N-terminus or C-terminus of a cancer-specific protein, and using a nickel ion immobilization column for cancer Often, specific proteins are purified by affinity. (Sker ra A. et al., Biotechnology (1 9 9 1)) Mar; 9 (3) 2 7 3 1 8 and Crowe J et al., Methods Mo 1 Biol.
- cancer-specific antigenic proteins such as CTA often have multiple cysteine thiol (one SH) groups in the sequence, and disulfide is present between protein molecules. (-S- S-) tends to combine to form multimers.
- Some proteins can be purified as high-purity proteins by improving their properties, that is, by forming monomers by cross-linking within the molecule by refolding operation.
- cancer-specific antigenic proteins such as CTA are unlikely to form intramolecular disulfide bonds, and monomers tend not to be obtained by refolding procedures. Therefore, when purifying cancer-specific antigen proteins such as CTA, there are various problems as described below.
- Non-Patent Document 4 Preparative Biochem & Biotech, 3 5: 1 1 9-1 3 4, 2 0 0 5
- NY-ESO-1 it was reported that it became a huge aggregate of 200 nm (Non-patent document 5; Clin Cancer Res, 1 0: 2 8 7 9-2 8 9 0, 2 0 0 4).
- Patent Document 2 As an attempt to solve the above problems, a method was proposed in which MAGE-A 3 CTA was reduced with 2-mercaptoethanol and then reacted with iodide iodide to block-protect the thiol group by carboxymethylation ( Patent Document 2; WO 9 9/40 1 8 8 publication).
- a method for selectively protecting such a thiol group carboxymethylation with thioacetic acid or iodide acetate is generally performed.
- this method irreversibly blocks the thiol group, so that there is a disadvantage that in the case of a protein antigen epitope containing cysteine, the epitope is inactivated.
- RED 0 X Reagent Dal Yuthion or Dalutathione Oxidant or Is reconfiguration (refolding)
- Non-patent literature 6 Behring Inst Mitt. 1 9 8 8 Au; (8 3): 2 4 6-9) and insulin
- Non-patent literature 8 J Biol Chem. 1 9 9 2 Jan 5; 2 6 7 (1): 4 1 9-2 5, Non-Patent Document 8; Anal Chem. 1 9 9 2 Mar 1; 6 4 (5): 5 0 7-1
- a sulfate (one SH) group is converted to sulfo (one SS O.3) by the action of sodium and then refolded and then refolded.
- Is a well-known method for example, dry sulfonated human immune globulin blood donation 1 I Refer to the package insert
- Patent Document 1 W0 9 8/0 9 6 5 0
- Patent Document 2 W0 9 9/4 0 1 8 8
- Non-Patent Document 1 v an der Bruggen P, et al., Science; 2 5 4: 1 6 4 3-7 (1 9 9 1)
- Non-Patent Document 2 De Plaen E, et al., Immunogene tics; 4 0: 3 6 0-9 (1 9 9 4)
- Non-Patent Document 3 Rogner UC, et al., Genomics. 2 9: 7 2 5-3 1 (1 9 9 5)
- Non-Patent Document 4 Preparative Bioc em & Biotech, 3 5: 1 1 9-1 3 4, 2 0 0 5
- Non-Patent Document 5 Clin Cancer Res, 1 0: 2 8 7 9-2 8 9 0, 2 0 0 4
- Non-Patent Document 6 Behring Inst Mitt, 1 9 8 8 A ug; (8 3): 2 4 6-9
- Non-Patent Document 7 JB iol Chem. 1 9 9 2 Jan 5; 2 6 7 (1): 4 1 9— 2 5
- Non-Patent Document 8 Ana Chen. 1 9 9 2 Mar 1; 6 4 (5): 5 0 7-1 1 Disclosure of the Invention
- An object of the present invention is to provide a protein complex and a method for producing the same, which have solved the drawbacks of the prior art described above.
- the object of the present invention is to provide a method for producing a complex of a protein antigen that is purified in high yield without causing aggregation due to formation of intermolecular disulfide bonds of the protein antigen to form a complex. There is to be.
- the present inventor has sulfonated a thiol group of a protein having two or more cysteine residues in the molecule, and then purified while maintaining the monomer by a method such as column chromatography. It has been found that the above object can be achieved by forming a complex with a fine particle forming substance such as a hydrophobic polysaccharide, and reducing the sulfonated protein in the complex if necessary.
- the method for producing a protein complex of the present invention is based on the above findings. More specifically, the protein embedding agent forms a complex with an embedding agent having a protein having two or more cysteine residues in the molecule.
- a method for producing a complex which is characterized by modifying and purifying a cysteine residue of the protein before embedding in the embedding agent.
- a cancer-specific protein antigen such as CTA having two or more cysteine residues in the molecule can be obtained in a high yield as a stable monomer.
- a polymer carrier such as a hydrophobic polysaccharide.
- the thiol group of the sulfonated recombinant cancer-specific protein antigen can be restored without forming disulfide bonds between the protein molecules before or after the formation.
- the cancer-specific protein antigen is stabilized by oxidative sulfonation of a cancer-specific protein antigen having two or more cysteine residues in the molecule. It is presumed that intermolecular bond formation of the protein antigen is effectively prevented, and that it is possible to purify the protein antigen monomer with high yield.
- cancer-specific antigen such as CTA (a kind of protein antigen)
- CTA a kind of protein antigen
- many cancer-specific antigens contain an odd number of cysteine residues. These systems do not form intramolecular disulfide bonds and exist as thiol groups, or a certain amount contributes to the formation of CTA multimers by forming disulfide bonds between molecules. Therefore, it is presumed that the presence of such a thiol group hindered the purification of cancer-specific antigen with good yield.
- the present invention is also applicable to oncogene products such as ErbB-2 protein and tumor blood vessel antigen protein (VEGFR).
- oncogene products such as ErbB-2 protein and tumor blood vessel antigen protein (VEGFR).
- VEGFR tumor blood vessel antigen protein
- the present invention includes, for example, the following aspects.
- a method for producing a protein complex wherein the protein is purified by modifying a cysteine residue before embedding in the embedding agent.
- [7] The method for producing a protein complex according to any one of [1] to [6], wherein the protein is cancer testis antigen (CTA).
- CTA cancer testis antigen
- [8] The method for producing a protein complex according to [7], wherein the cancer testis antigen (CTA) is a recombinant testis antigen expressed using recombinant Escherichia coli.
- CTA cancer testis antigen
- a package comprising at least a hydrophobized polysaccharide (A) and a sulfonated recombinant testis antigen (B) embedded in the molecule and having two or more cysteine residues in the molecule Buried protein antigen.
- A hydrophobized polysaccharide
- B sulfonated recombinant testis antigen
- a CHP-CTA vaccine comprising at least a hydrophobized polysaccharide (A) and a sulfonated recombinant testis antigen (CTA) embedded therein.
- the recombinant testis antigen is MAG EA 1, M AG EA 2, MAG EA 3, MAG EA 4, MAG EA 5, MA GEA 6, MA GEA 7, MAG EA 8, MA GEA 9, MAG EA 1 MAG E family from 0, MAG EA ll, MA GEA 1 2, MA GEB 1, AG EB 2, MAG EB 3, MAG EB 4, MAG ECI, MAG EC 2
- a cancer-specific protein antigen and a method for producing the same capable of suitably purifying the protein antigen while suppressing polymerization and multimerization of the cancer-specific protein antigen as much as possible.
- Fig. 1 shows that MAG E-A4 is present in the supernatant of the disruption solution by reducing SDS-PAGE in the cell disruption solution obtained by culturing MAG E-A4 recombinant E. coli.
- Fig. 2 shows the disruption solution of His-Tag- MA GE-A4-expressing E. coli and the reduced fraction of the crude fraction on a Ni column with SDS-PAGE. It indicates that MAGE-A4 with a purity of at least% is obtained.
- Fig. 3 shows the crude purified H s — T ag — MA G E — A 4 and its non-reduced S D S — P A G E.
- the crudely purified MAGE—A 4 before the protection reaction shows that it is an assembly of multimers (6 0 — 1 1 0 kd) and structural isomers (3 8 — 4 8 kd) in the non-reduced state, and sulfonated protection It shows that the reaction converges to one band (49 kd).
- Figure 4 shows the non-reduced SDS-PAGE when treated under the harsh conditions of the crude purified His-Tag-MAGE-A4 and its sulfonated protectors.
- Figure 4 shows that sulfonated protectors are stable to heat and freeze-thaw, while polymerized and aggregated by heating prior to protection.
- FIG. 5 is a purification chart using a D E A E column. Two elution peaks were observed here, but SDS—PAGE and RPC were indistinguishable and presumed to be due to differences in conformation.
- FIG. 6 is a chart showing the results of ELI S POT analysis of CHP—His—Tag—MAG E—A4. Compared to Negative Control (Non-treat, CHP-Her 2), significantly more INF-aspots were observed, confirming that CHP-MAGE was taken up by DC and activated CTL. It was.
- Figure 7 shows the result of ELISPOT assembly for CHP—MAG E—A 4 It is a chart which shows. Compared to negative control (Non-treat, CHP—Her 2), significantly more I FN—aspots were observed, and CHP—H is —Tag—MAGE—A4 was taken up by dendritic cells and CTL It was confirmed that it was activated.
- Figure 8 is a graph showing the embedded product size distribution (according to constant peak intensity) shown in Table 2.
- the anti-cancer protein vaccine of the present invention is formulated by embedding a cancer-specific protein antigen having two or more cysteine residues in a molecule in a polymer carrier such as a hydrophobic polysaccharide.
- the protein antigen may be embedded in a hydrophobized polysaccharide or the like while being sulfonated, but may be reduced immediately before embedding in the hydrophobized polysaccharide, or may be embedded in the hydrophobized polysaccharide. It can be reduced after a while. This reduction method can be achieved by the action of 2-mercaptoethanol, dithiothreitol, cysteine, etc. of 2 mM or more. ''
- the polymer carrier to be used in the present invention has a nanogel-forming property by embedding the hydrophobic part of a cancer-specific protein antigen such as ribosome, hydrophobized polysaccharide, iscomatrix, etc.
- the child carrier can be used without any particular limitation.
- Hydrophobized polysaccharides (used to mean “hydrophobized polysaccharide aggregate microparticles”; the same applies hereinafter) are, for example, Akiyoshi et al., Macromolecules, .6, p p. 3 0 6 2-3 0 6 8, 1 9 9 3; Akiyoshi et al., J. Proc. Japan. Acad., 7 1, 7 1 B, p.
- the polysaccharide in the hydrophobized polysaccharide is not particularly limited as long as it is a high molecule in which sugar residues are glycosidically bonded.
- a sugar residue constituting the polysaccharide for example, a residue derived from a saccharide such as glucose, mannose, galactose, or fucose, or a saccharide such as disaccharide or oligosaccharide can be used.
- the sugar residue may be 1, 2—, 1, 3—, 1, 4 —, or 1, 6-glycoside linkage, and the linkage may be either ⁇ _ or i8-type linkage.
- the polysaccharide may be either linear or branched.
- a glucose residue is preferable, and as the polysaccharide, natural or synthetic pullulan, dextran, amylose, amylopectin, or mannan, preferably mannan or pullulan can be used.
- the hydrophobic group is not particularly limited, and one having a high encapsulation rate can be selected according to the isoelectric point of the molecular weight of the antigen to be embedded (or encapsulated). From the viewpoint of safety as a vaccine formulation, 1 to 5 mono- and double-stranded alkyl groups or sterol residues that are metabolized and safe as hydrophobic groups per 10 monosaccharides (by weight) 5% or less) It is desirable to introduce it.
- sterol residues examples include cholesterol, stigmasterol, 6-sitosterol, lanosterol, ergosterol residues, and the like. From the viewpoint of safety as a vaccine formulation, cholesterol residues may be used. desirable. Also Archi As the alkyl group, an alkyl group having preferably 20 or less carbon atoms, more preferably 10 to 18 carbon atoms can be used, and these may be either linear or branched.
- the primary hydroxyl group of 1 to 5 sugar units per 100 sugar units constituting the polysaccharide is represented by the following formula (I):
- R represents an alkyl group or a sterol residue
- m represents 0 or 1
- n represents It represents an arbitrary positive integer
- R represents an alkyl group or sterol residue
- m represents 0 or 1
- n represents It represents an arbitrary positive integer
- alkyl group or sterol residue those described above can be preferably used, and n is preferably 1-8.
- the hydrophobized polysaccharides may be those linked via a linker as described in JP-A-7-973333.
- hydrophobic polysaccharides More specifically, in the present invention, the following hydrophobic polysaccharides:
- CHP, CHM, etc. are, as necessary, commercially available products (for example, commercially available products from Nippon Oil & Fat Co., Ltd. with molecular weights of 60,000, 100,000, etc .; sugar residues 1 There are about 1.6 cholesterols per 0).
- the cancer-specific protein antigen to be embedded in a polymer carrier such as the above-mentioned hydrophobized polysaccharide is a protein antibody specifically expressed in cancer cells having two or more cysteine residues in the molecule. Use the field.
- the following can be preferably used as the cancer-specific protein antigen.
- CTA Cancer testis antigen
- Oncogene products such as E r b B _ 2 protein and antigen protein (V E G F R) of tumor blood vessels
- the hydrophobic polysaccharide and antigen are mixed at room temperature in the presence of a denaturing agent such as urea, and then the denaturing agent is removed by ultrafiltration or gel chromatography.
- a denaturing agent such as urea
- the vaccine preparation that can be produced according to the present invention can immunize the animal by administering a predetermined amount thereof to the animal in the same manner as other known vaccine preparations. Can be evaluated.
- the administration route of the vaccine preparation of the present invention is generally subcutaneous or intradermal injection.
- the dose of the actin preparation of the present invention required for immunization can be determined as appropriate.
- the normal dose is preferably about 50 to 150 mg as an antigen, preferably about 100 to 600 mg. It is appropriate to administer 3 to 30 doses, using the Z dose as a guide. It is also effective to use an immunostimulant such as GM-CSF, IL-2, CpG or ⁇ K-4 3 2 together.
- Recombinant E. coli is prepared by incorporating C ⁇ D DNA into a common plasmid.
- the DNA sequence of CTA is known (US Pat. No. 5 3 4 2 7 7 4 etc.) and can be easily achieved by bio-manufacturers.
- sulfonating a cancer-specific protein antigen having two or more cysteine residues in the molecule for example, as sulfonation conditions, in the presence of 8 M urea or 6 M guanidine, 3 0-3 0 0 0 m (preferably 2 00 — 50 O mM) of sodium sulfite, 6 — 60 0 m (preferably 3 0 — 10 O mM) of tetrathionic acid is allowed to act at 10 to 50 ° C. preferable.
- the purity of the sulfonated protein antigen can be checked by reverse phase HPLC or electrophoresis. This stability can be confirmed, for example, by one band by electrophoresis even when heated in a neutral buffer solution at 60 ° C. for 10 minutes. In the absence of sulfonated protection, the polymer band considered to be a polymer multimer increases. (Refer to the electrophoresis pattern corresponding to Examples below)
- CHP is dissolved in a denaturing agent solution such as 6-8 M urea or 6 M guanidine, or CHP is dissolved in water or a buffer solution, and the weight ratio to protein 1 is 1
- a denaturing agent solution such as 6-8 M urea or 6 M guanidine
- CHP is dissolved in water or a buffer solution
- the weight ratio to protein 1 is 1
- GHP normal temperature is sufficient, but it can be done under heating.
- the molecular weight of C H P is desirably 5 0 — 100 k d.
- C H P is commercially available from, for example, Nippon Oil & Fat Co., Ltd.
- the particle size distribution of the complex of the hydrophobic polysaccharide (A) of the present invention and the protein antigen (B) can be confirmed using a particle size distribution meter (DRI). (See Figure 8 in the example)
- Embedding can be checked by GPC (gel permeation chromatography; see, for example, the description of “CHP embedding” below).
- GPC gel permeation chromatography
- the peaks of CHP and cancer-specific antigen protein are completely moved to the position of the CHP peak by embedding, so this “embedding” can be confirmed.
- the yield of the “embedding” is desirably 95% or more, and more preferably 99% or more.
- the yield of “embedding” can be determined.
- the yield of “embedding” is desirably 95% or more, and more preferably 99% or more.
- V it can be measured in an experimental system in which antigen-presenting cells and killer or helper T cells are combined.
- the embedded protein antigen is incorporated into antigen-presenting cells such as dendritic cells, and the activation of killer T cells by the antigen-presenting cells is measured by ELISA (Enzyme-1 inked immunosorbent). assay) and ELISP ⁇ It can be confirmed by the T method (Enzyme-linked-ImmunoS ⁇ ⁇ ⁇ ). In such an experimental system, antigen activity can be observed.
- the embedded protein antigen of the present invention can be used as a vaccine. Since this vaccine is a so-called “antigen drug”, it is usually possible to obtain an immunity effect in an amount smaller than that of a so-called “antibody drug” by an order of magnitude or more.
- preferred embodiments of the vaccine are as follows.
- Sulfonated recombinant cancer-specific protein antigen obtained by reacting sulfite and tetrathionate with a recombinant cancer-specific protein antigen (hereinafter referred to as “SH antigen”) expressed using recombinant E. coli ( CHP—sulfonated antigen vaccine (hereinafter referred to as “sulfonated antigen”), in which sulfonated recombinant testis antigen is embedded in a hydrophobic polysaccharide.
- SH antigen recombinant cancer-specific protein antigen expressed using recombinant E. coli ( CHP—sulfonated antigen vaccine (hereinafter referred to as “sulfonated antigen”), in which sulfonated recombinant testis antigen is embedded in a hydrophobic polysaccharide.
- the recombinant cancer-specific protein antigen of (1) or (2) above is MAGE—A1, MAGE-A2, MAGE—A3, MAGE—A4, MAGE—A5, MAGE-A6. , MAGE— A 7, MAG E-A 8, AGE-A 9, MAGE-A 1 0, MAGE-A ll
- Recombinant testis antigen (1) or (2) above is NY — ESO— 1, LAGE family—, GAG E family, SAG E family, XA GE family CHP selected from one or more CHP — C TA sulfonated antigen vaccine or its reduced form CHP—CTASH antigen vaccine.
- CHP—His Tag C TA sulfonated antigen vaccine or CHP wherein the recombinant cancer testis antigen of (1) or (2) above is His — Tag— C TA with the addition of His — T ag _His Tag C TA SH antigen vaccine.
- Reverse primer 5 '-AAG C T T C T C AT G C T C AGA C T C C C T C-3'
- RT-PCR was performed on RNA derived from the melanoma cell line SK—ME L—37, using as a primer, and as a result, BamHI sites (G GAT CC) and Hindi II sites on both ends.
- AAGCTT MAG E— ⁇ 4 full length c D NA was obtained (conducted by Dr. Yao-T seng Chen of Cornell University School of Medicine, USA).
- PQE9ZMAGE—A4 plasmid was obtained (performed by Dr. Yao-Tseng Chen, Cornell University School of Medicine).
- This seed stock is inoculated into LB medium containing antibiotics (25 ug ZmL kanamycin, lOO ug ZmL ampicillin) and cultured. After incubation, the antibiotic-containing medium is removed by centrifugation, and the antibiotic-free LB medium is added. After washing with medium and changing the medium, it was mixed with an equal volume of 40% aqueous glycerol and stored at 80 ° C to make MCB.
- antibiotics 25 ug ZmL kanamycin, lOO ug ZmL ampicillin
- Antibiotic-free LB medium (10 L) was inoculated with 5 mL of MAG E—A 4 MCB. 3 Pre-incubate for 6 to 15 hours at 7 ° C, 2550 rpm, lv vm, incubate 10 L of the preculture with 20 0 L of LB medium, 30 ° C, 60 Culturing was started at rpm and lv vm.
- OD 600 is about 1
- IPTG is added at a final concentration of 0.3 mm o 1 ZL
- induction is started, and DO control is kept above about 60% (about 4.5 ppm) by stirring. After 5 hours from the start of induction, the culture was terminated.
- Figure 1 shows the electrophoresis pattern of the supernatant of the lysate obtained.
- Fig. 1 (Number of cell disruption passes and solubilization) shows the reduction of bacterial cell lysate obtained by culturing MA GE-A4 recombinant E. coli. A 4 is present.
- M Molecular weight marker 1
- P C Positive control
- C S Culture supernatant
- S Supernatant
- P Sediment Production Example 2
- MAG E—A 4 protein was separated from the crushed filtrate using a N i — ⁇ column (QI AG ENN i — NT agarose, 25 cm diameter, approx. 4 L). Perform step elution as follows. (Flow rate 5 6 [table 1 ]
- Figure 2 shows the electrophoresis pattern of the eluate obtained.
- the meaning of each symbol is as follows.
- Figure 2 shows the reduced SDS-PAGE of the His-Tag-MAGE-A4-expressing E. coli lysate and the crudely purified fraction of the Ni-NTA affinity column. 9 Indicates that MAG E-A 4 with a purity of 5% or more can be obtained.
- Millipore Pellicon 2 Ultracell PLCGC 1 0 K 0. 1 m 2 X Concentrate the Ni — NTA column elution pool to approximately 5 mg / mL using 1 flat membrane (Millipore), then 8 times after concentration The buffer was exchanged with 20 mM Tris-HCl (H8.0) in excess of the amount to remove imidazole.
- Example 1 The reaction of Example 1 was also performed in the presence of 6 M guanidine instead of 8 M urea.
- Example 1 Using the “crudely purified His—Tag—MAG E—A 4” obtained in Example 1, the following experiments of Example 3 to Example 8 were conducted.
- Fig. 3 shows crude purified His — Tag— MAG E— A 4 and its sulfonated protectant.
- 4 is a collection of multimers (6 0 — 1 1 0 kd) and structural isomers (3 8-48 kd). It shows convergence to the band (49 kd).
- the following table shows the impurity profile at each purification step from the supernatant of the cell disruption solution (total protein amount of 57 g). It was shown that impurities such as endotoxin, host-derived protein, and DNA were efficiently removed from the Ni—N TA crude protein.
- the immune activity of the CHP—His_Tag—MAGE—A4 vaccine thus obtained was confirmed using the ELISPOT method as follows.
- the suspension was suspended in the medium to a concentration of 0 6 ZmL.
- the size distribution of the embedded product was measured.
- the measurement conditions are shown in Table 5 below. As shown.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2649269A CA2649269C (en) | 2006-04-11 | 2007-04-11 | Protein complex and process for producing the same |
US12/226,199 US20120029175A1 (en) | 2006-04-11 | 2007-04-11 | Protein Complex and Process for Producing the Same |
EP07741817.6A EP2006302B1 (en) | 2006-04-11 | 2007-04-11 | Protein complex and process for production thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-108668 | 2006-04-11 | ||
JP2006108668A JP5170976B2 (ja) | 2006-04-11 | 2006-04-11 | タンパク質複合体およびその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007119859A1 true WO2007119859A1 (ja) | 2007-10-25 |
Family
ID=38609618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/058381 WO2007119859A1 (ja) | 2006-04-11 | 2007-04-11 | タンパク質複合体およびその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20120029175A1 (ja) |
EP (1) | EP2006302B1 (ja) |
JP (1) | JP5170976B2 (ja) |
CN (1) | CN101501069A (ja) |
CA (1) | CA2649269C (ja) |
WO (1) | WO2007119859A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140322344A1 (en) * | 2011-08-31 | 2014-10-30 | National University Corporation Tokyo Medical And Dental University | Vaccine preparation for cancer treatment |
US11179450B2 (en) | 2013-10-01 | 2021-11-23 | Mie University | Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106243213B (zh) * | 2016-08-15 | 2018-11-09 | 广州安博泰医疗生物科技有限公司 | 一种肿瘤相关抗原XAGE-1b短肽及应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6169801A (ja) | 1984-09-12 | 1986-04-10 | Junzo Sunamoto | 天然由来多糖誘導体およびその製造方法 |
WO1987001729A1 (en) * | 1985-09-19 | 1987-03-26 | Celltech Limited | Polypeptide production |
JPH03292301A (ja) | 1990-04-11 | 1991-12-24 | Nippon Oil & Fats Co Ltd | 多糖類―ステロール誘導体とその製造法 |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
JPH0797333A (ja) | 1993-08-04 | 1995-04-11 | Takeda Chem Ind Ltd | 超分子構造型集合体 |
WO1998000650A1 (en) | 1996-07-03 | 1998-01-08 | Prattville Manufacturing, Inc. | Split backplate for brake pad |
WO1998009650A1 (fr) | 1996-09-06 | 1998-03-12 | Mitsubishi Chemical Corporation | Preparations vaccinales |
WO1999040188A2 (en) | 1998-02-05 | 1999-08-12 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations |
WO2005032475A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus adjuvant |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69621409T2 (de) * | 1995-12-27 | 2003-01-16 | Kao Corp | Polysaccharidderivat, Verfahren zu deren Herstellung und seine Verwendung |
US20030143240A1 (en) * | 2000-06-27 | 2003-07-31 | Cabezon-Silva Teresa Elisa Virginia | Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen |
-
2006
- 2006-04-11 JP JP2006108668A patent/JP5170976B2/ja not_active Expired - Fee Related
-
2007
- 2007-04-11 US US12/226,199 patent/US20120029175A1/en not_active Abandoned
- 2007-04-11 CA CA2649269A patent/CA2649269C/en not_active Expired - Fee Related
- 2007-04-11 CN CNA200780013167XA patent/CN101501069A/zh active Pending
- 2007-04-11 EP EP07741817.6A patent/EP2006302B1/en not_active Expired - Fee Related
- 2007-04-11 WO PCT/JP2007/058381 patent/WO2007119859A1/ja active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6169801A (ja) | 1984-09-12 | 1986-04-10 | Junzo Sunamoto | 天然由来多糖誘導体およびその製造方法 |
WO1987001729A1 (en) * | 1985-09-19 | 1987-03-26 | Celltech Limited | Polypeptide production |
JPH03292301A (ja) | 1990-04-11 | 1991-12-24 | Nippon Oil & Fats Co Ltd | 多糖類―ステロール誘導体とその製造法 |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
JPH0797333A (ja) | 1993-08-04 | 1995-04-11 | Takeda Chem Ind Ltd | 超分子構造型集合体 |
WO1998000650A1 (en) | 1996-07-03 | 1998-01-08 | Prattville Manufacturing, Inc. | Split backplate for brake pad |
WO1998009650A1 (fr) | 1996-09-06 | 1998-03-12 | Mitsubishi Chemical Corporation | Preparations vaccinales |
WO1999040188A2 (en) | 1998-02-05 | 1999-08-12 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations |
WO2005032475A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus adjuvant |
Non-Patent Citations (26)
Title |
---|
AKIYOSHI ET AL., J. PROC. JAPAN. ACAD., vol. 71, no. 71B, 1995, pages 15 |
AKIYOSHI ET AL., MACROMOLECULES, vol. 6, 1993, pages 3062 - 3068 |
ANAL. CHEM., vol. 64, no. 5, 1 March 1992 (1992-03-01), pages 507 - 11 |
BEHRING INST MITT., vol. 83, August 1988 (1988-08-01), pages 246 - 9 |
BUTTS C. ET AL., J. CLIN. ONCOL., vol. 20-23, no. 27, 2005, pages 6674 - 81 |
CHEN YT ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 94, 1997, pages 1914 - 8 |
CLIN. CANCER RES., vol. 10, 2004, pages 2879 - 2890 |
CROWE J. ET AL., METHODS MOL. BIOL., vol. 31, 1994, pages 371 - 387 |
DAVIS D. ET AL., P. NATUR. ACAD. SCI., vol. 101, no. 29, 2004, pages 10697 |
DAVIS I.D. ET AL.: "Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans", PNAS, vol. 101, no. 29, 20 July 2004 (2004-07-20), pages 10697 - 10702, XP002451138 * |
DE PLAEN E. ET AL., IMMUNOGENETICS, vol. 40, 1994, pages 360 - 9 |
HEATH W.F. ET AL.: "(A-C-B) Human Proinsulin, a Novel Insulin Agonist and Intermediate in the Synthesis of Biosynthetic Human Insulin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 1, 1992, pages 419 - 425, XP003018538 * |
J. BIOL. CHEM., vol. 267, no. 1, 5 January 1992 (1992-01-05), pages 419 - 25 |
MIYAHARA Y. ET AL., CLIN. CANCER RES., vol. 11, no. 5, 2005, pages 5581 - 9 |
NISHIKAWA, MACROMOLECULES, vol. 27, 1994, pages 7654 - 7659 |
NORTH S. ET AL., EXPERT REV. VACCINES, vol. 4, no. 3, 2005, pages 249 - 57 |
PREPARATIVE BIOCHEM. & BIOTECH., vol. 35, 2005, pages 119 - 134 |
ROGNER UC ET AL., GENOMICS, vol. 29, 1995, pages 725 - 31 |
SAHIN, U. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 11810 - 3 |
See also references of EP2006302A4 |
SHIBATA R. ET AL., INT. J. CANCER, vol. 48, no. 3, 30 May 1991 (1991-05-30), pages 434 - 42 |
SHIBATA R. ET AL.: "INDUCTION OF IN VITRO AND IN VIVO ANTI-TUMOR RESPONSES BY SENSITIZATION OF MICE WITH LIPOSOMES CONTAINING A CRUDE BUTANOL EXTRACT OF LEUKEMIA CELLS AND TRANSFERRED INTER-MEMBRANOUSLY WITH CELL-SURFACE PROTEINS", INT. J. CANCER, vol. 48, no. 3, 1991, pages 434 - 442, XP003018539 * |
SKERRA A. ET AL., BIOTECHNOLOGY, vol. 9, no. 3, March 1991 (1991-03-01), pages 273 - 8 |
SUNAMOTO J. ET AL., ANN. NY ACAD. SCI., vol. 613, 1990, pages 116 - 27 |
TURECI 0. ET AL., CANCER RES., vol. 56, 1996, pages 4766 - 72 |
VAN DER BRUGGEN P. ET AL., SCIENCE, vol. 254, 1991, pages 1643 - 7 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140322344A1 (en) * | 2011-08-31 | 2014-10-30 | National University Corporation Tokyo Medical And Dental University | Vaccine preparation for cancer treatment |
JPWO2013031882A1 (ja) * | 2011-08-31 | 2015-03-23 | 国立大学法人三重大学 | がん治療用ワクチン製剤 |
US11179450B2 (en) | 2013-10-01 | 2021-11-23 | Mie University | Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells |
Also Published As
Publication number | Publication date |
---|---|
US20120029175A1 (en) | 2012-02-02 |
EP2006302B1 (en) | 2014-03-12 |
CA2649269C (en) | 2014-08-05 |
JP5170976B2 (ja) | 2013-03-27 |
EP2006302A4 (en) | 2011-02-16 |
JP2007277202A (ja) | 2007-10-25 |
EP2006302A9 (en) | 2009-08-05 |
EP2006302A2 (en) | 2008-12-24 |
CN101501069A (zh) | 2009-08-05 |
CA2649269A1 (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2584482C (en) | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination | |
CN107050440B (zh) | 疫苗组合物和其使用方法 | |
US9562070B2 (en) | Induction of tumor immunity by variants of folate binding protein | |
CN107522772B (zh) | 短肽、其作为疫苗佐剂的应用及以所述短肽作为疫苗佐剂的疫苗 | |
van Bergen et al. | Get into the groove! Targeting antigens to MHC class II | |
JP4033497B2 (ja) | ワクチン製剤 | |
WO2018074558A1 (ja) | 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン | |
WO2007119859A1 (ja) | タンパク質複合体およびその製造方法 | |
WO2010138123A1 (en) | P53 fusion proteins and methods of making and using thereof | |
CA2475526A1 (en) | Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours | |
CN114790248B (zh) | MUC1-PDL1-IgG1 Fc肿瘤疫苗及其制备方法和应用 | |
WO2010150708A1 (ja) | 蛋白質の修飾剤 | |
JP2023515850A (ja) | 腫瘍免疫増強剤、その調製方法および適用 | |
MXPA00007677A (en) | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination | |
CN112891513A (zh) | 一种阳离子多肽-热休克蛋白-miRNA基因复合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780013167.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07741817 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2649269 Country of ref document: CA Ref document number: 12226199 Country of ref document: US Ref document number: 8549/DELNP/2008 Country of ref document: IN Ref document number: 2007741817 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |